Breast cancer incidence, by stage at diagnosis, and mortality
in 21 European countries in the era of mammography screening:
an international population-based study

J 2026

Breast cancer incidence, by stage at diagnosis, and mortality in 21 European countries in the era of mammography screening: an international population-based study

CARDOSO, Rafael; Idris OLA; Lina JANSEN; Monika HACKL; Petra IHLE et al.

Základní údaje

Originální název

Breast cancer incidence, by stage at diagnosis, and mortality in 21 European countries in the era of mammography screening: an international population-based study

Autoři

CARDOSO, Rafael; Idris OLA; Lina JANSEN; Monika HACKL; Petra IHLE; Julie FRANCART; Van Damme NANCY; Zdravka VALERIANOVA; Trayan ATANASOV; Ondřej MÁJEK ; Ondřej NGO; Kaire INNOS; Margit MAGI; Sandrine Dabakuyo YONLI; Anne-Sophie WORONOFF; Brigitte TRETARRE; Florence PONCET; Alexander KATALINIC; Paul M WALSH; Ieva VINCERZ; Laura STEPONAVICIENE; De Munck LINDA; Sabine SIESLING; Tom Borge JOHANNESEN; Solveig HOFVIND; Rita CALISTO; Maria Jose BENTO; Da Costa Filipa ALVES; Alexandra MAYER; Antonio LOURENCO; Tina ZAGAR; Sonja TOMSIC; Miguel RODRIGUEZ-BARRANCO; Maria-Jose SANCHEZ; Arantza Lopez De Munain MARQUES; Rafael MARCOS-GRAGERA; Arantza SANVISENS; Antonia Sanchez GIL; Maria-Dolores Chirlaque LOPEZ; Jaume GALCERAN; Francina SALADIE; Kristina SUNDQUIST; Jan SUNDQUIST; Mats-Ake PERSSON; Marcel BLUM; Mohsen MOUSAVI; Von Moos ROGER; Olena SUMKINA; Anton RYZHOV; Michael HOFFMEISTER a Hermann BRENNER

Vydání

The Lancet Regional Health - Europe, AMSTERDAM, Elsevier Ltd, 2026, 2666-7762

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 13.000 v roce 2024

Označené pro přenos do RIV

Ano

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Breast cancer; Cancer screening; Mammography; Population-based study; Cancer epidemiology

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 9. 4. 2026 08:50, Mgr. Tereza Miškechová

Anotace

V originále

Background Mammography screening programmes have been widely implemented across European countries over the past 40 years with the main aim to detect breast cancer earlier and thereby reduce breast cancer mortality. This study aimed to analyse and compare changes over time in breast cancer incidence, by stage at diagnosis, and breast cancer mortality across countries in relation to the timing of screening implementation and age at diagnosis. Methods In this population-based study conducted in 21 European countries, data from cancer registries covering over 3 million female patients diagnosed with breast cancer, along with data from national statistical offices from 1978 to 2019 were analysed. Annual age-standardised breast cancer incidence rates (by stage and age at diagnosis) and age-standardised breast cancer mortality rates were calculated. Average annual percent changes (AAPCs) in these metrics within 10 years before and 10 years after screening implementation were estimated. Findings Overall, breast cancer incidence rates increased over the study period, with the largest increases observed in the first two decades (1978-1987 and 1988-1997), and AAPCs of up to 4.55 (95% confidence interval, CI, 2.56-6.57). In contrast, breast cancer mortality rates decreased most predominantly in the last two decades (1998-2007 and 2008-2018/19), with AAPCs down to-5.40 (95% CI, -9.70 to-0.89). The largest increases in incidence were seen for in situ and stage I cancers (AAPCs ranging from non-significant to 12.03 (95% CI, 7.40-16.86) following screening implementation). Incidence of stage IV cancer declined or remained stable in most countries, with AAPCs down to-6.16 (95% CI, -8.28 to-4.00) after screening introduction. These trends were particularly pronounced among age groups targeted by screening (mostly 50-69 years). Breast cancer mortality rates declined by up to 3 percent annually after screening initiation (lowest AAPC estimate-3.29 (95% CI, -6.26 to-0.23); yet, AAPCs as low as-2.54 (95% CI, -3.15 to-1.93) were also observed before introduction of screening programmes in countries where implementation occurred later, in the 2000s. Interpretation This study suggests that mammography screening has influenced trends in breast cancer incidence and mortality in European countries. The results point to the contribution of mammography screening, alongside advances in diagnostics and treatment, to the observed reductions in breast cancer mortality. Copyright (c) 2025 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Citovat

CARDOSO, Rafael; Idris OLA; Lina JANSEN; Monika HACKL; Petra IHLE; Julie FRANCART; Van Damme NANCY; Zdravka VALERIANOVA; Trayan ATANASOV; Ondřej MÁJEK; Ondřej NGO; Kaire INNOS; Margit MAGI; Sandrine Dabakuyo YONLI; Anne-Sophie WORONOFF; Brigitte TRETARRE; Florence PONCET; Alexander KATALINIC; Paul M WALSH; Ieva VINCERZ; Laura STEPONAVICIENE; De Munck LINDA; Sabine SIESLING; Tom Borge JOHANNESEN; Solveig HOFVIND; Rita CALISTO; Maria Jose BENTO; Da Costa Filipa ALVES; Alexandra MAYER; Antonio LOURENCO; Tina ZAGAR; Sonja TOMSIC; Miguel RODRIGUEZ-BARRANCO; Maria-Jose SANCHEZ; Arantza Lopez De Munain MARQUES; Rafael MARCOS-GRAGERA; Arantza SANVISENS; Antonia Sanchez GIL; Maria-Dolores Chirlaque LOPEZ; Jaume GALCERAN; Francina SALADIE; Kristina SUNDQUIST; Jan SUNDQUIST; Mats-Ake PERSSON; Marcel BLUM; Mohsen MOUSAVI; Von Moos ROGER; Olena SUMKINA; Anton RYZHOV; Michael HOFFMEISTER a Hermann BRENNER. Breast cancer incidence, by stage at diagnosis, and mortality in 21 European countries in the era of mammography screening: an international population-based study. The Lancet Regional Health - Europe. AMSTERDAM: Elsevier Ltd, 2026, roč. 62, March 2026, s. 1-16. ISSN 2666-7762. Dostupné z: https://doi.org/10.1016/j.lanepe.2025.101574.

@article{2562477,
   author = {Cardoso, Rafael and Ola, Idris and Jansen, Lina and Hackl, Monika and Ihle, Petra and Francart, Julie and Nancy, Van Damme and Valerianova, Zdravka and Atanasov, Trayan and Májek, Ondřej and Ngo, Ondřej and Innos, Kaire and Magi, Margit and Yonli, Sandrine Dabakuyo and Woronoff, AnneandSophie and Tretarre, Brigitte and Poncet, Florence and Katalinic, Alexander and Walsh, Paul M and Vincerz, Ieva and Steponaviciene, Laura and Linda, De Munck and Siesling, Sabine and Johannesen, Tom Borge and Hofvind, Solveig and Calisto, Rita and Bento, Maria Jose and Alves, Da Costa Filipa and Mayer, Alexandra and Lourenco, Antonio and Zagar, Tina and Tomsic, Sonja and RodriguezandBarranco, Miguel and Sanchez, MariaandJose and Marques, Arantza Lopez De Munain and MarcosandGragera, Rafael and Sanvisens, Arantza and Gil, Antonia Sanchez and Lopez, MariaandDolores Chirlaque and Galceran, Jaume and Saladie, Francina and Sundquist, Kristina and Sundquist, Jan and Persson, MatsandAke and Blum, Marcel and Mousavi, Mohsen and Roger, Von Moos and Sumkina, Olena and Ryzhov, Anton and Hoffmeister, Michael and Brenner, Hermann},
   article_location = {AMSTERDAM},
   article_number = {March 2026},
   doi = {https://doi.org/10.1016/j.lanepe.2025.101574},
   keywords = {Breast cancer; Cancer screening; Mammography; Population-based study; Cancer epidemiology},
   language = {eng},
   issn = {2666-7762},
   journal = {The Lancet Regional Health - Europe},
   title = {Breast cancer incidence, by stage at diagnosis, and mortality in 21 European countries in the era of mammography screening: an international population-based study},
   url = {https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(25)00366-7/fulltext},
   volume = {62},
   year = {2026}
}

TY  - JOUR
ID  - 2562477
AU  - Cardoso, Rafael - Ola, Idris - Jansen, Lina - Hackl, Monika - Ihle, Petra - Francart, Julie - Nancy, Van Damme - Valerianova, Zdravka - Atanasov, Trayan - Májek, Ondřej - Ngo, Ondřej - Innos, Kaire - Magi, Margit - Yonli, Sandrine Dabakuyo - Woronoff, Anne-Sophie - Tretarre, Brigitte - Poncet, Florence - Katalinic, Alexander - Walsh, Paul M - Vincerz, Ieva - Steponaviciene, Laura - Linda, De Munck - Siesling, Sabine - Johannesen, Tom Borge - Hofvind, Solveig - Calisto, Rita - Bento, Maria Jose - Alves, Da Costa Filipa - Mayer, Alexandra - Lourenco, Antonio - Zagar, Tina - Tomsic, Sonja - Rodriguez-Barranco, Miguel - Sanchez, Maria-Jose - Marques, Arantza Lopez De Munain - Marcos-Gragera, Rafael - Sanvisens, Arantza - Gil, Antonia Sanchez - Lopez, Maria-Dolores Chirlaque - Galceran, Jaume - Saladie, Francina - Sundquist, Kristina - Sundquist, Jan - Persson, Mats-Ake - Blum, Marcel - Mousavi, Mohsen - Roger, Von Moos - Sumkina, Olena - Ryzhov, Anton - Hoffmeister, Michael - Brenner, Hermann
PY  - 2026
TI  - Breast cancer incidence, by stage at diagnosis, and mortality in 21 European countries in the era of mammography screening: an international population-based study
JF  - The Lancet Regional Health - Europe
VL  - 62
IS  - March 2026
SP  - 1-16
EP  - 1-16
PB  - Elsevier Ltd
SN  - 26667762
KW  - Breast cancer
KW  - Cancer screening
KW  - Mammography
KW  - Population-based study
KW  - Cancer epidemiology
UR  - https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(25)00366-7/fulltext
N2  - Background Mammography screening programmes have been widely implemented across European countries over the past 40 years with the main aim to detect breast cancer earlier and thereby reduce breast cancer mortality. This study aimed to analyse and compare changes over time in breast cancer incidence, by stage at diagnosis, and breast cancer mortality across countries in relation to the timing of screening implementation and age at diagnosis. Methods In this population-based study conducted in 21 European countries, data from cancer registries covering over 3 million female patients diagnosed with breast cancer, along with data from national statistical offices from 1978 to 2019 were analysed. Annual age-standardised breast cancer incidence rates (by stage and age at diagnosis) and age-standardised breast cancer mortality rates were calculated. Average annual percent changes (AAPCs) in these metrics within 10 years before and 10 years after screening implementation were estimated. Findings Overall, breast cancer incidence rates increased over the study period, with the largest increases observed in the first two decades (1978-1987 and 1988-1997), and AAPCs of up to 4.55 (95% confidence interval, CI, 2.56-6.57). In contrast, breast cancer mortality rates decreased most predominantly in the last two decades (1998-2007 and 2008-2018/19), with AAPCs down to-5.40 (95% CI, -9.70 to-0.89). The largest increases in incidence were seen for in situ and stage I cancers (AAPCs ranging from non-significant to 12.03 (95% CI, 7.40-16.86) following screening implementation). Incidence of stage IV cancer declined or remained stable in most countries, with AAPCs down to-6.16 (95% CI, -8.28 to-4.00) after screening introduction. These trends were particularly pronounced among age groups targeted by screening (mostly 50-69 years). Breast cancer mortality rates declined by up to 3 percent annually after screening initiation (lowest AAPC estimate-3.29 (95% CI, -6.26 to-0.23); yet, AAPCs as low as-2.54 (95% CI, -3.15 to-1.93) were also observed before introduction of screening programmes in countries where implementation occurred later, in the 2000s. Interpretation This study suggests that mammography screening has influenced trends in breast cancer incidence and mortality in European countries. The results point to the contribution of mammography screening, alongside advances in diagnostics and treatment, to the observed reductions in breast cancer mortality. Copyright (c) 2025 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
ER  -

CARDOSO, Rafael; Idris OLA; Lina JANSEN; Monika HACKL; Petra IHLE; Julie FRANCART; Van Damme NANCY; Zdravka VALERIANOVA; Trayan ATANASOV; Ondřej MÁJEK; Ondřej NGO; Kaire INNOS; Margit MAGI; Sandrine Dabakuyo YONLI; Anne-Sophie WORONOFF; Brigitte TRETARRE; Florence PONCET; Alexander KATALINIC; Paul M WALSH; Ieva VINCERZ; Laura STEPONAVICIENE; De Munck LINDA; Sabine SIESLING; Tom Borge JOHANNESEN; Solveig HOFVIND; Rita CALISTO; Maria Jose BENTO; Da Costa Filipa ALVES; Alexandra MAYER; Antonio LOURENCO; Tina ZAGAR; Sonja TOMSIC; Miguel RODRIGUEZ-BARRANCO; Maria-Jose SANCHEZ; Arantza Lopez De Munain MARQUES; Rafael MARCOS-GRAGERA; Arantza SANVISENS; Antonia Sanchez GIL; Maria-Dolores Chirlaque LOPEZ; Jaume GALCERAN; Francina SALADIE; Kristina SUNDQUIST; Jan SUNDQUIST; Mats-Ake PERSSON; Marcel BLUM; Mohsen MOUSAVI; Von Moos ROGER; Olena SUMKINA; Anton RYZHOV; Michael HOFFMEISTER a Hermann BRENNER. Breast cancer incidence, by stage at diagnosis, and mortality in 21 European countries in the era of mammography screening: an international population-based study. \textit{The Lancet Regional Health - Europe}. AMSTERDAM: Elsevier Ltd, 2026, roč.~62, March 2026, s.~1-16. ISSN~2666-7762. Dostupné z: https://doi.org/10.1016/j.lanepe.2025.101574.

Přehled o publikaci